Hemogenyx Pharmaceuticals PLC Announces Final Results
-
Palace boss Glasner says contract talks on hold due to hectic schedule
-
Netflix to launch FIFA World Cup video game
-
Venezuela says oil exports continue normally despite Trump 'blockade'
-
German MPs approve 50 bn euros in military purchases
-
India v South Africa 4th T20 abandoned due to fog
-
Hydrogen plays part in global warming: study
-
EU's Mercosur trade deal hits French, Italian roadblock
-
What next for Belarus after US deal on prisoners, sanctions?
-
Brazil Senate debates bill that could slash Bolsonaro jail term
-
Coe shares 'frustration' over marathon record despite Kenyan's doping ban
-
Stolen Bruce Lee statue 'returns' to Bosnia town
-
Veteran Suarez signs new Inter Miami contract
-
Warner Bros rejects Paramount bid, sticks with Netflix
-
Crude prices surge after Trump orders Venezuela oil blockade
-
Balkan nations offer lessons on handling cow virus sowing turmoil
-
French readers lap up Sarkozy's prison diaries
-
UK PM warns Abramovich 'clock is ticking' over Chelsea sale fund
-
Warner Bros. Discovery rejects Paramount bid
-
Winners of 2026 World Cup to pocket $50 million in prize money
-
World no. 1 Alcaraz ends 'incredible ride' with coach Ferrero
-
World number one Alcaraz announces 'difficult' split with coach Ferrero
-
Iran boxer sentenced to death at 'imminent' risk of execution: rights groups
-
Snicko operator admits error that led to Carey's Ashes reprieve
-
Finland PM apologises to Asian countries over MPs' mocking posts
-
Doctors in England go on strike for 14th time
-
Romania journalists back media outlet that sparked graft protests
-
Rob Reiner's son awaiting court appearance on murder charges
-
Ghana's Highlife finds its rhythm on UNESCO world stage
-
Stocks gain as traders bet on interest rate moves
-
France probes 'foreign interference' after malware found on ferry
-
Europe's Ariane 6 rocket puts EU navigation satellites in orbit
-
Bleak end to the year as German business morale drops
-
Hundreds queue at Louvre museum as strike vote delays opening
-
Bondi shooting shocks, angers Australia's Jewish community
-
Markets rise even as US jobs data fail to boost rate cut bets
-
Senegal talisman Mane overcame grief to become an African icon
-
Carey pays tribute to late father after home Ashes century
-
'Many lessons to be learned' from Winter Games preparations, says ski chief
-
Emotional Carey slams ton to give Australia upper hand in 3rd Ashes Test
-
Asian markets mixed as US jobs data fails to boost rate cut hopes
-
Carey slams ton as Australia seize upper hand in third Ashes Test
-
Bondi shooting shocks, angers Australia Jewish community
-
Myanmar junta seeks to prosecute hundreds for election 'disruption'
-
West Indies hope Christmas comes early in must-win New Zealand Test
-
Knicks beat Spurs in NBA Cup final to end 52-year trophy drought
-
Khawaja revels in late lifeline as Australia 194-5 in 3rd Ashes Test
-
Grief and fear as Sydney's Jewish community mourns 'Bondi rabbi'
-
Trump orders blockade of 'sanctioned' Venezuela oil tankers
-
Brazil Senate to debate bill to slash Bolsonaro jail term
-
New Zealand ex-top cop avoids jail time for child abuse, bestiality offences
NYSE - LSE
| SCS | 0.12% | 16.14 | $ | |
| RBGPF | 0.5% | 82.01 | $ | |
| CMSC | -0.21% | 23.29 | $ | |
| BTI | 0.2% | 57.405 | $ | |
| GSK | 0.8% | 49.175 | $ | |
| BCE | -0.17% | 23.29 | $ | |
| RIO | 1.5% | 77.145 | $ | |
| BCC | -0.03% | 75.815 | $ | |
| NGG | 1.63% | 77.025 | $ | |
| RYCEF | 0.8% | 14.92 | $ | |
| RELX | 0.02% | 40.83 | $ | |
| CMSD | -0.52% | 23.26 | $ | |
| AZN | -0.46% | 90.93 | $ | |
| JRI | -0.67% | 13.42 | $ | |
| BP | 1.47% | 34.265 | $ | |
| VOD | 0.59% | 12.775 | $ |
Hemogenyx Pharmaceuticals PLC Announces Final Results
LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at https://hemogenyx.com/.
Key Highlights
The Company commenced Phase I clinical trials of its HG-CT-1 product candidate.
Continuing development of Chimeric Bait Receptor antiviral/biodefence platform, which gained attention at major conferences.
Successfully raised £3.9 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2024, and a further £1.3 million in early 2025.
Fuller details of these developments are contained in the full, unedited text of the final results for the year ended 31 December 2024 below.
http://www.rns-pdf.londonstockexchange.com/rns/3187G_1-2025-4-25.pdf
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
Th.Gonzalez--AT